Status:
COMPLETED
Xpert MTB/RIF Ultra Trial
Lead Sponsor:
Nestani Tukvadze
Collaborating Sponsors:
National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia
Conditions:
Tuberculosis (TB)
Pulmonary TB
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Tuberculosis (TB) is the leading cause of death caused by infectious agent globally. Estimated 10 million people get ill with TB every year and in 2022 globally there was an increase in Tuberculosis c...
Detailed Description
BACKGROUND INFORMATION The use of the rapid diagnostic test Xpert MTB/RIF (Xpert) for simultaneous detection of Mycobacterium tuberculosis and Rifampicin resistance has been scaled up in recent years ...
Eligibility Criteria
Inclusion
- Presumptive pulmonary TB patients, as defined by the NTP treatment guidelines.
- Adults 18 years old and above
Exclusion
- Patients with symptoms which are only attributable to extra-pulmonary TB
- Patients below the age of 18 years
Key Trial Info
Start Date :
May 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 24 2023
Estimated Enrollment :
778 Patients enrolled
Trial Details
Trial ID
NCT07135622
Start Date
May 27 2019
End Date
February 24 2023
Last Update
August 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Center for Tuberculosis and Lung Diseases
Tbilisi, Georgia, 0101